Concortis-Levena

In 2008, Concortis Biosystems was established with the goal to better serve the scientific and pharmaceutical community with high quality antibody drug conjugate (ADC) reagents and services. In 2013, Sorrento acquired Concortis, creating a top tier ADC company. The combination of G-MAB™ (fully human antibody library) with Concortis proprietary toxins, linkers, and conjugation methods has the potential to generate industry-leading, 3rd generation ADCs.

Concortis is currently exploring over 20 different ADC options (pre-clinical) with applications in oncology and beyond. On October 19, 2015, Sorrento announced the creation of Levena Biopharma as an independent entity to offer the market a broad range of ADC services from the initiation of an ADC project through cGMP manufacturing of ADCs to phase I/II clinical studies. For detailed information, please visit www.levenabiopharma.com